TLR8 and HIV-1 infection: This suggests that combining SMACm with the TLR8 agonist may be effective for in vivo reservoir elimination by reducing the viral reservoir as well as inducing antiviral adaptive immunity to control HIV-1 infection over time, thereby further decreasing the HIV-1 reservoir.